Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Dear Colleagues,

Liver cancer is a topic which is receiving increasing attention. Hepatocellular carcinomas are still the primary liver cancers with the highest prevalence and death toll worldwide. Intrahepatic cholangiocarcinoma is also on the rise, and an ever-increasing number of rare liver cancers are being reported. Epidemiology, pathogenesis and response to surgical, locoregional and systemic treatments are all elements of particular interest which need further elucidation by future studies. This Special Issue of Livers will cover all aspects, and welcomes both original research and comprehensive review papers to guide a wide readership toward the most recent and ground-breaking research in this complex field.

Dr. Francesco Tovoli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Livers is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Hepatocellular carcinoma
• Cholangiocellular carcinoma
• Liver surgery
• Percutaneous ablation techniques
• Immune checkpoint inhibitors
• Atezolizumab
• Bevacizumab
• Sorafenib
• Regorafenib